No Data
Meipu Medical (301033): Profits exceed expectations, new products quickly gaining momentum.
Subject: The company released the third quarter report of 24, 24Q1-3, revenue of 0.191 billion yuan (+30.98%), net income attributable to mother of 0.053 billion yuan (+107.68%), non-net profit of 0.046 billion yuan (+
Meepo Medical (301033): Performance grows rapidly year-on-year, aiming to build high-end neurosurgery for overseas markets.
Event: On October 29, 2024, the company released the third quarter report of 2024. During the reporting period, the company achieved revenue of 0.191 billion yuan (+30.98%), net income attributable to the parent company of 0.053 billion yuan (+10%).
Maipu Medical: Report for the third quarter of 2024
Meipu Medical (301033.SZ): Achieved revenue of 0.191 billion yuan in the first three quarters, a year-on-year increase of 30.98%.
Great Wisdom reported on October 28 that Meipu Medical (301033.SZ) released its third quarter report for 2024, achieving revenue of 0.191 billion yuan for the first three quarters, a year-on-year growth of 30.98%; net income attributable to shareholders of the listed company was 52.803 million yuan, a year-on-year increase of 107.68%; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was 46.0877 million yuan, a year-on-year increase of 108.37%; basic earnings per share was 0.80 yuan. The main reason for the increase in revenue was the orderly implementation of the operation objectives set at the beginning of the year, along with an increase in marketing efforts.
Express News | MaiPu Medical: The net income for the first three quarters was 52.803 million yuan, a year-on-year increase of 107.68%.
Meipu Medical (301033): The domestic product penetration rate is rapidly increasing, the overseas brand influence continues to expand, and the company is entering a rapid development period.
Performance Brief The company released its third quarter report for 2024, achieving revenue of 0.191 billion yuan in the first three quarters, a year-on-year growth of 30.98%; achieving a net income attributable to the mother of 0.053 billion yuan, a year-on-year growth of 107.68%. For the third quarter alone.
No Data
